October 21, 2015 writer

TSO3: Q3 2015 Financial Results Conference Call

Québec City, October 21, 2015 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Company”) an innovator in sterilization technology for medical devices in healthcare settings, will hold a conference call on Wednesday, November 4, 2015 at 10:30 a.m. Eastern time to discuss its financial results for the third quarter ended September 30, 2015. Financial results will be issued in a press release prior to the call.

TSO3 President and CEO Mr. Ric Rumble and Interim CFO Mrs. Éléna Simard-Veilleux will host the conference call, followed by a question and answer period.

Date:                                       Wednesday, November 4, 2015

Time:                                       10:30 a.m. Eastern time (7:30 a.m. Pacific time)

Toll-free dial-in number:           1 888-231-8191

International dial-in number:     1 514-807-9895 (Montreal); 1 647-427-7450 (Toronto)

Conference ID:                         1062091

Analysts and institutional investors are invited to participate to the call. Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Liolios Group at 1 949-574-3860.

The conference call will be broadcast live and available for replay at:

http://event.on24.com/r.htm?e=1062091&s=1&k=1928F249DE2CA2F29C0A5B94AC4BE718 and via the investor relations section of the Company’s website at www.tso3.com.

About TSO3

Founded in 1998, TSO3’s activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

For more information about TSO3, visit the Company’s Web site at www.tso3.com or contact Liolios Group at  949 574-3860 or email TOS@liolios.com.

The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful. 

The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.


Back to Posts